Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00590109 · ClinicalTrials.gov registry record
Germline BRCA1 and BRCA2 Mutations in Jewish Women Affected by Breast Cancer
A clinical trial, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- 383
- Enrollment target
NCT00590109: Completed study, sponsored by Memorial Sloan Kettering Cancer Center.
NCT00590109 is a clinical trial that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 383 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00590109 has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- 383 participants
- Enrollment target
Study Summary
The purpose of this project is to further characterize inherited predisposition to breast cancer mediated by specific BRCA alleles (BRACA1 185delAG and 5382insC; BRCA2 6174delT) among Jewish women.
Interventions
- OTHER Questionnaire
- OTHER Blood test
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 383 participants |
| Start Date | 1997-03 |
| Est. Completion | 2021-12-22 |
What the finished NCT00590109 record still lists
NCT00590109 is an observational study that tracks outcomes without assigning an intervention. The registered 383 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 2 interventions - of which Questionnaire is the first listed.
NCT00590109 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00590109 about?
NCT00590109 is a clinical study titled "Germline BRCA1 and BRCA2 Mutations in Jewish Women Affected by Breast Cancer". The purpose of this project is to further characterize inherited predisposition to breast cancer mediated by specific BRCA alleles (BRACA1 185delAG and 5382insC; BRCA2 6174delT) among Jewish women.
What is the current status of trial NCT00590109?
This trial is currently completed. The enrollment target is 383 participants. The study started on 1997-03. Estimated completion is 2021-12-22.
What interventions are being tested in trial NCT00590109?
The interventions under investigation include: Questionnaire (OTHER), Blood test (OTHER).
Who is sponsoring clinical trial NCT00590109?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06056830 · 383 participants · Phase 3
Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Radical Prostatectomy
- NCT06277661 · 384 participants · NA
The Mom and Infant Outcomes (MOMI) Study
- NCT06372964 · 384 participants · Phase 3
Multicenter Study of Lumateperone for the Treatment of Bipolar Depression in Pediatric Patients
- NCT06501040 · 384 participants · NA
Increasing Knowledge and Interest in Cancer Clinical Trials
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia